Targeting Inflammatory Pathways: A Phase 2 Trial Of The Jak-Inhibitor Ruxolitinib In Combination With Exemestane For Aromatase Inhibitor-Resistant, Estrogen Receptor-Positive Breast Cancer
CANCER RESEARCH(2017)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要